Real-Life Clinical Outcomes of Aflibercept Biosimilar MY-1701P in the Treatment of Exudative Age-Related Macular Degeneration

ConditionsAge Related Macular Degeneration Exudative Age-Related Macular Degeneration Anti Vascular Endothelial Growth Factor

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age45-90

SponsorSaglik Bilimleri Universitesi

About this trial

In this study, patients receiving Eylea treatment will be treated with Yesafili, a biosimilar molecule, and routine examination results will be noted.

Eligibility criteria

Qualifiers

Patients aged between 45 and 90 years with active neovascular age-related macular degeneration (nAMD)

who show signs of disease activity on routine ophthalmologic examination and optical coherence tomography (OCT)

for whom intravitreal injection has already been clinically indicated

Disqualifiers

Patients younger than 45 years or older than 90 years

History of stroke, cerebrovascular event, myocardial infarction, or coronary stent placement within the last six months

Presence of uveitis

Media opacity preventing adequate retinal imaging (e.g., corneal opacity, mature cataract)

Trial design

Treatments tested in this trial

Aflibercept biosimilar (MY-1701P)

Treatment groups

54 Participants

are divided into 1 treatment group

Locations

Prof. Dr. Cemil Taşcıoğlu City Hospital34384, Istanbulşişli, Turkey (Türkiye)

Sponsors and collaborators

Saglik Bilimleri Universitesi

Lead sponsor

Source ClinicalTrials.gov